

The specification has been amended to include the Sequence Listing submitted herewith on separate sheets. Entry of the Sequence Listing does not raise the issue of new matter as the sequence information contained therein is presented in the application as originally filed. The Sequence Listing submitted herewith corrects errors in the Sequence Listing submitted January 29, 2001, specifically, SEQ ID NOs:19 and 20 properly recite Lys as the C-terminal amino acid. The computer readable copy of the Sequence Listing submitted herewith is the same as the attached paper copy of that Listing.

Claims 30-35 have been cancelled and claims 64 and 66 have been amended.

The original oath/declaration is attached.

In response to the Examiner's requirement for restriction, Applicants elect with traverse the subject matter of Group I (claims 30-35, 56-70) for prosecution in this application. Non-elected subject matter will be deleted in due course.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

This application is submitted to be in condition for allowance and a Notice to that effect is requested.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

64. (Amended) A peptide sequence according to claim 60, characterized in that the host cell is a [mycoplasma] mycobacterium.

66. (Amended) A reactant for detecting an anti-HBHA antibody in a biological fluid, consisting of:

a) the HBHA protein purified from a preparation of [mycoplasma] mycobacterium cell walls, or a fragment thereof, determined by epitope mapping;

b) a fragment thereof comprised in the C-terminal portion of that protein, and in particular in the last 50 terminal amino acids shown in Figure 10, according to claim 56; or

c) a recombinant peptide sequence according to any claim 60.